Abstract
In the recent study of spironolactone for hirsutism in polycystic ovary syndrome (2005;39:1517-21), the following change should be made to Table 1: under the Results column for the Moghetti et al. study, a Placebo heading should appear over the last item in both the Mean Shaft Diameter and the F-G Score columns.
Letters are subject to review prior to acceptance. They should address areas related to pharmacy practice, research, or education, or articles recently published. Corrections of previously published material also are accepted. Letters are limited to no more than five authors. In cases where adverse drug effects are described, the Naranjo ADR probability scale should be used to determine the likelihood that the adverse effect was drug-related (Clin Pharmacol Ther 1981;30:239-45). Text: limit 500 words. References: limit 5. Art: limit 1 table or figure.